Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune announced promising interim results from its Phase 1b/2a trial of the ACI-35.030 vaccine for early Alzheimer’s disease. The trial showed 100% of older patients generated high levels of anti-pTau antibodies post-vaccination, significantly exceeding pre-vaccination levels. The vaccine was safe and well-tolerated, with no adverse events reported. The findings support advancing ACI-35.030 into Phase 2/3 trials. This innovation highlights the potential for early intervention in Alzheimer’s, utilizing a cutting-edge vaccine formulation aimed at combating Tau pathology.
AC Immune SA (NASDAQ: ACIU) has initiated a first-in-human study of ACI-12589, a novel PET imaging tracer for Parkinson's disease (PD). This tracer aims to accurately detect pathological alpha-synuclein deposits in the brain, a hallmark of PD. Supported by the Michael J. Fox Foundation, results are expected in Q3 2021. In preclinical studies, ACI-12589 displayed improved sensitivity and specificity compared to previous candidates, potentially leading to earlier diagnosis and effective monitoring of disease progression.
AC Immune SA (NASDAQ: ACIU) announced advancements in its small molecule and antibody therapeutic programs targeting the NLRP3 inflammasome, crucial for neurodegenerative diseases like Alzheimer’s. The company has identified potent small molecule NLRP3 inhibitors, demonstrating significant biological activity in animal models. AC Immune plans to initiate in vivo proof-of-concept studies by year-end to evaluate CNS delivery and efficacy. Additionally, high-affinity antibodies that inhibit ASC-mediated inflammatory responses are under development. These pipeline advancements highlight AC Immune's commitment to addressing neurodegeneration.
AC Immune (NASDAQ: ACIU) received a USD 600,000 grant from Target ALS to advance a collaboration with Massachusetts General Hospital. The funding will accelerate the development of proprietary immuno-assays for detecting TDP-43, a protein linked to several neurodegenerative diseases, including ALS. These assays aim to improve early diagnostics, enabling targeted treatment strategies. AC Immune's CEO highlighted the potential of these assays and the ongoing development of an anti-TDP-43 therapeutic antibody. This positions the company as a leader in precision medicine for neurodegenerative conditions.
AC Immune has announced the appointment of Prof. June as a scientific leader, reinforcing the company's expertise in neurodegeneration. Prof. June is recognized globally for his work in immune tolerance and adoptive immunotherapy. This leadership change aligns with AC Immune's strategy to enhance its research capabilities, particularly in neurodegenerative diseases. The company is expected to leverage his knowledge to advance its pipeline and foster innovation.
AC Immune announces the appointment of Prof. Johannes R. Streffer as Chief Medical Officer, effective January 2021. With extensive experience in neurology and psychiatry, Prof. Streffer aims to enhance AC Immune's pipeline targeting neurodegenerative diseases. Previously at UCB Biopharma, he led advancements in neuroscience and clinical study design, particularly in Alzheimer’s disease. The company’s pipeline includes nine therapeutic candidates, with collaborations involving major pharmaceutical firms like Genentech and Eli Lilly.
AC Immune SA (NASDAQ: ACIU) reported Q3 2020 financial results, achieving revenues of CHF 1.1 million amid a significant decline of CHF 32.1 million year-over-year. The company holds CHF 246.6 million in cash, funding operations until Q1 2024. A Phase 1 trial with Eli Lilly for Morphomer™ Tau showed promising pharmacokinetics, while the TDP-43 therapeutic program advances with EU grant support. However, a Phase 2 trial of the anti-Tau antibody did not meet primary efficacy endpoints. R&D expenditures increased by over 35%, and the net loss for Q3 reached CHF 19 million.
AC Immune (NASDAQ: ACIU), a leading biopharmaceutical company focused on neurodegenerative diseases, announced its participation in the Jefferies Virtual London Healthcare Conference on November 18, 2020. CEO Prof. Andrea Pfeifer will discuss the company’s strategies for 2021, particularly its candidates targeting TAR DNA-binding protein 43 (TDP-43), which is critical in conditions like Alzheimer’s and amyotrophic lateral sclerosis (ALS). The presentation aims to highlight their innovative approach to precision medicine in treating these diseases.
AC Immune SA has entered a strategic partnership with WuXi Biologics to advance its TDP-43 antibody into clinical development for NeuroOrphan indications. This agreement leverages AC Immune's drug discovery platforms and WuXi's manufacturing capabilities to address the significant unmet medical needs related to TDP-43-related neurodegenerative diseases. The collaboration aims to expedite the drug development process, with AC Immune retaining all intellectual property rights. This partnership highlights the company's growth and commitment to bringing innovative treatments to market.
AC Immune (NASDAQ: ACIU) has secured a €1.45M grant from the EU's Joint Programme – Neurodegenerative Disease Research (JPND). This funding will support the development of the first-in-class TDP-43 PET tracer in collaboration with the JPND ImageTDP-43 consortium, aimed at detecting neurodegenerative diseases including ALS and FTLD-TDP. The company emphasizes its innovative Morphomer™ platform's role in advancing precision medicine, as highlighted by CEO Prof. Andrea Pfeifer. The TDP-43 PET tracer shows strong binding to pathological aggregates, enhancing diagnostics and potential treatments for Alzheimer’s disease.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
